X4 Pharmaceuticals Advances CN Treatment with Mavorixafor Trials
Company Announcements

X4 Pharmaceuticals Advances CN Treatment with Mavorixafor Trials

X4 Pharmaceuticals (XFOR) has issued an announcement.

X4 Pharmaceuticals has shared promising interim results from their Phase 2 clinical trial of mavorixafor in treating chronic neutropenia (CN), revealing that the drug was well tolerated and effectively increased absolute neutrophil counts. This has led to the initiation of a pivotal Phase 3 trial aimed at further evaluating mavorixafor’s safety and efficacy. The positive outcomes from the Phase 2 trial, which involved both monotherapy and combination therapy with G-CSF, are significant for patients with CN, who currently have limited treatment options.

For an in-depth examination of XFOR stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyX4 Pharmaceuticals price target lowered to $1.50 from $5 at H.C. Wainwright
TipRanks Auto-Generated NewsdeskX4 Pharmaceuticals Reports Positive Trial Results and Progress
TheFlyX4 Pharmaceuticals price target lowered to $4 from $5 at Stifel
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App